Literature DB >> 29474237

Trends in Cervical Cancer Screening in California's Family Planning Program.

Heike Thiel de Bocanegra1,2, Sandy K Navarro1, Narissa J Nonzee3, Sitaram Vangala4, Xinkai Zhou4, Charlene Chang5, Anna-Barbara Moscicki5.   

Abstract

OBJECTIVE: Guidelines recommend 3-year cervical cancer screening intervals to avoid unnecessary invasive procedures; however, regular testing remains critical. We evaluated trends in cervical cancer screening among low-income women receiving family planning-related services and their association with patient and provider characteristics.
MATERIALS AND METHODS: Using claims and enrollment data from California's publicly funded family planning program, we identified 540,026 women with a clinician visit at 216 sites between 2011 and 2015. We calculated guideline adherent cervical cancer testing rates for 6-month periods among women aged 21 to 24, 25 to 29, and 30 to 64 years. We also calculated guideline adherent chlamydia testing for women aged 21 to 24 years.
RESULTS: Having a 3-year cervical cancer screening test declined for all age groups. The odds of cervical cancer screening declined for women aged 21 to 24 years by an estimated 11% every 6 months (odds ratio [OR] = 0.90, 95% confidence interval [CI] = 0.89-0.90), a significantly greater decline than for the other age groups. Among women aged 21 to 29 years, the decrease was significantly larger for Latina (ratio of ORs = 0.95, 95% CI = 0.95-0.96) and Spanish-speaking (ratio of ORs = 0.95, 95% CI = 0.95-0.96) women compared with non-Latina and non-Spanish-speaking women. A smaller decline was seen for chlamydia screening.
CONCLUSIONS: Changes in screening interval guidelines are associated with overall decreased screening. This trend was strongest among women aged 21 to 24 years, even as they continued to be screened appropriately for chlamydia, suggesting many missed opportunities. Efforts to reduce unnecessary cervical cancer screening should be monitored to maintain appropriate screening rates to avoid advanced-stage diagnoses and higher health care costs.

Entities:  

Mesh:

Year:  2018        PMID: 29474237      PMCID: PMC6014881          DOI: 10.1097/LGT.0000000000000376

Source DB:  PubMed          Journal:  J Low Genit Tract Dis        ISSN: 1089-2591            Impact factor:   1.925


  16 in total

1.  International incidence rates of invasive cervical cancer after introduction of cytological screening.

Authors:  L Gustafsson; J Pontén; M Zack; H O Adami
Journal:  Cancer Causes Control       Date:  1997-09       Impact factor: 2.506

2.  Breast and cervical cancer screening rates of subgroups of Asian American women in California.

Authors:  Marjorie Kagawa-Singer; Nadereh Pourat; Nancy Breen; Steven Coughlin; Teresa Abend McLean; Timothy S McNeel; Ninez A Ponce
Journal:  Med Care Res Rev       Date:  2007-09-05       Impact factor: 3.929

3.  Cervical Cancer Screening Guideline Adherence Before and After Guideline Changes in Pennsylvania Medicaid.

Authors:  Natasha Parekh; Julie M Donohue; Aiju Men; Jennifer Corbelli; Marian Jarlenski
Journal:  Obstet Gynecol       Date:  2017-01       Impact factor: 7.661

4.  American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer.

Authors:  Debbie Saslow; Diane Solomon; Herschel W Lawson; Maureen Killackey; Shalini L Kulasingam; Joanna Cain; Francisco A R Garcia; Ann T Moriarty; Alan G Waxman; David C Wilbur; Nicolas Wentzensen; Levi S Downs; Mark Spitzer; Anna-Barbara Moscicki; Eduardo L Franco; Mark H Stoler; Mark Schiffman; Philip E Castle; Evan R Myers
Journal:  CA Cancer J Clin       Date:  2012-03-14       Impact factor: 508.702

5.  ACOG Practice Bulletin Number 131: Screening for cervical cancer.

Authors: 
Journal:  Obstet Gynecol       Date:  2012-11       Impact factor: 7.661

6.  2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors.

Authors:  L Stewart Massad; Mark H Einstein; Warner K Huh; Hormuzd A Katki; Walter K Kinney; Mark Schiffman; Diane Solomon; Nicolas Wentzensen; Herschel W Lawson
Journal:  Obstet Gynecol       Date:  2013-04       Impact factor: 7.661

7.  Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement.

Authors:  Virginia A Moyer
Journal:  Ann Intern Med       Date:  2012-06-19       Impact factor: 25.391

Review 8.  Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis.

Authors:  M Arbyn; M Kyrgiou; C Simoens; A O Raifu; G Koliopoulos; P Martin-Hirsch; W Prendiville; E Paraskevaidis
Journal:  BMJ       Date:  2008-09-18

Review 9.  Fertility and early pregnancy outcomes after treatment for cervical intraepithelial neoplasia: systematic review and meta-analysis.

Authors:  Maria Kyrgiou; Anita Mitra; Marc Arbyn; Sofia Melina Stasinou; Pierre Martin-Hirsch; Phillip Bennett; Evangelos Paraskevaidis
Journal:  BMJ       Date:  2014-10-28

10.  Cancer Screening Test Use - United States, 2015.

Authors:  Arica White; Trevor D Thompson; Mary C White; Susan A Sabatino; Janet de Moor; Paul V Doria-Rose; Ann M Geiger; Lisa C Richardson
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2017-03-03       Impact factor: 17.586

View more
  2 in total

1.  Impact of an educational tool on young women's knowledge of cervical cancer screening recommendations.

Authors:  Heike Thiel de Bocanegra; Christine Dehlendorf; Miriam Kuppermann; Sitaram S Vangala; Anna-Barbara Moscicki
Journal:  Cancer Causes Control       Date:  2022-03-21       Impact factor: 2.532

2.  Should Cervical Cancer Screening be Performed Before the Age of 25 Years?

Authors:  Anna-Barbara Moscicki; Rebecca B Perkins; Marion Saville; Julia M L Brotherton
Journal:  J Low Genit Tract Dis       Date:  2018-10       Impact factor: 1.925

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.